Identifying novel treatment options for ovarian carcinosarcoma

Identifying novel treatment options for ovarian carcinosarcoma

Project details

Ovarian carcinosarcoma (OCS) is the most lethal gynaecological cancer, and as a rare cancer has few evidence-based treatment options because supportive data is simply not available. Standard treatment for OCS comprises surgery with radiotherapy and platinum-based chemotherapy. Most patients relapse within one year of treatment and have a median overall survival of less than two years.

This project will involve the analysis of ovarian carcinosarcoma patient samples using a variety of techniques including genomics, 3D organoid culture, live cell imaging, immune profiling, drug library screening, and CRISPR screening. The aim is to identify pathways that mediate response to conventional chemotherapeutics and that show potential for targeting with novel agents, to inform clinical trial design in this under-studied cancer.

About our research group

The Scott Laboratory has a strong emphasis on research that has potential for clinical translation. Our relatively large laboratory of 15 is made up of a combination of clinician scientists, post-doctoral fellows, students and research assistants. We have a strong collaborative ethic and while the lab is working on two main projects, rare cancer and ovarian cancer, technical expertise and resources are shared between both groups. There is a variety of expertise within the group including bioinformatics, genomics and cell biology.


Dr Holly Barker in the lab
ACRF Cancer Biology and Stem Cells division

Professor Clare Scott

Professor Clare Scott
Joint Division Head

Project Type: